Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 5:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 679 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mild Alzheimer Disease Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)

NCT02615002
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Piromelatine, Placebo
Drug
Lead sponsor
Neurim Pharmaceuticals Ltd.
Industry
Eligibility
60 Years to 85 Years
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
56
States / cities
Birmingham, Alabama • Tucson, Arizona • Bellflower, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Phase 2Phase 3 Interventional

Enhanced CBTi for Older Adult Sleep and Cognition

NCT05015803
View directory record Official record
Conditions
Insomnia, Alzheimers Disease Related Dementias
Interventions
CBTi with Application, CBTi, Sleep Hygiene Education
Combination Product · Behavioral
Lead sponsor
Penn State University
Other
Eligibility
60 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 7, 2026, 5:10 AM EDT
Not listed Phase 2 Interventional

Curcumin and Yoga Therapy for Those at Risk for Alzheimer's Disease

NCT01811381
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Curcumin, aerobic yoga, non aerobic yoga, Placebo
Drug · Behavioral · Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 7, 2026, 5:10 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

NCT06584357
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Biomarker Data Collection, MK6240
Other · Radiation
Lead sponsor
GAP Innovations, PBC
Industry
Eligibility
60 Years to 90 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
22
States / cities
Atlantis, Florida • Aventura, Florida • Clermont, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 7, 2026, 5:10 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Assessing Cognitive Decline at Home

NCT06704971
View directory record Official record
Conditions
Mild Cognitive Impairment, Mild Dementia, Dementia Alzheimers, Dementia, Memory Impairment, NPS
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
65 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 7, 2026, 5:10 AM EDT
Not listed Phase 2 Interventional

MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease

NCT05194163
View directory record Official record
Conditions
Alzheimer Disease
Interventions
MW150, Placebo
Drug
Lead sponsor
Neurokine Therapeutics
Industry
Eligibility
50 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment: Wearables

NCT05159557
View directory record Official record
Conditions
Dementia, Mild Cognitive Impairment, Alzheimer Disease
Interventions
In-Home Technology System, Limited In-Home Technology
Device
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 7, 2026, 5:10 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

OCT Angiography and NRAI in Dementia

NCT03761381
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Mild Cognitive Impairment
Interventions
Optical Coherence Tomography Angiography (OCTA) Imaging, Noninvasive Retinal Amyloid Imaging (NRAI)
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease

NCT05104463
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia
Interventions
CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107
Drug
Lead sponsor
CuraSen Therapeutics, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Scottsdale, Arizona • Lafayette, California • Boca Raton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 7, 2026, 5:10 AM EDT
Terminated Phase 3 Interventional Results available

2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)

NCT02916056
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Azeliragon 5mg
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
65
States / cities
Phoenix, Arizona • Tucson, Arizona • Bellflower, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)

NCT01044758
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI)
Interventions
Levetiracetam 62.5mg, Levetiracetam 125mg, Levetiracetam 250mg, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Not applicable Interventional

A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)

NCT05637801
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
Interventions
Spectris™ AD - Active, Spectris™ AD - Sham
Device
Lead sponsor
Cognito Therapeutics, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
68
States / cities
Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease

NCT01397539
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
BIIB037, Placebo
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
55 Years to 85 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Delray Beach, Florida • Orlando, Florida • Beachwood, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

NCT05686044
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Buntanetap/Posiphen, Placebo
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
54
States / cities
Gilbert, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study

NCT01230853
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Active Comparator: A, Placebo Comparator B, Active Comparator B, Placebo Comparator A
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Garden Grove, California • San Francisco, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease

NCT03402659
View directory record Official record
Conditions
Alzheimer Disease
Interventions
neflamapimod, placebo
Drug · Other
Lead sponsor
EIP Pharma Inc
Industry
Eligibility
55 Years to 85 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
16
States / cities
Long Beach, California • San Diego, California • Santa Ana, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 7, 2026, 5:10 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

NCT04576793
View directory record Official record
Conditions
Alzheimer Disease
Interventions
11C-ER176, 18F-MK6240, 18F-Florbetaben, Lumbar Puncture
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease

NCT00710684
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
SB-742457 15mg, SB-742457 35mg, Placebo, donepezil 5-10mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 85 Years
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Litchfield Park, Arizona • Fresno, California • Rancho Mirage, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 7, 2026, 5:10 AM EDT
Withdrawn Phase 2 Interventional

F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)

NCT02707978
View directory record Official record
Conditions
Alzheimer Disease
Interventions
F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Not applicable Interventional

Innovative Cognitive Impairment Case Finding and Engagement for Diverse Participation in Alzheimer's Disease Care, Treatment, And Research

NCT07016178
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Alzheimer Disease, Alzheimer's Disease (Incl Subtypes), Dementia, Cognitive Decline
Interventions
Acceptability and Feasibility of Twistle messaging for PDM+ patients
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older
Enrollment
3,454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

NCT05108922
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Alzheimer Disease
Interventions
Donanemab, Aducanumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years to 85 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
31
States / cities
Fullerton, California • Irvine, California • Sherman Oaks, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Early Phase 1 Interventional

Enhanced External Counterpulsation and Its Effects on Vascular Hemodynamics in Cognitively Impaired Patients

NCT01659398
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
External Counterpulsation (EECP)
Device
Lead sponsor
Patrick Moriarty, MD, FACP, FACC
Other
Eligibility
18 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Phase 2 Interventional

Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase

NCT01602393
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CHF 5074 1x, CHF 5074 2x, CHF 5074 3x
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 79 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Eatontown, New Jersey • Monroe Twp, New Jersey • Toms River, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)

NCT00857506
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Scottsdale, Arizona • Tucson, Arizona • Costa Mesa, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Oct 7, 2026, 5:10 AM EDT